Drug intelligence / Profile preview

VAI-VP705

Development stage: Phase 2
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VAI-VP705 is a recombinant human parvovirus B-19 vaccine composed of viral capsids that incorporate two B-19 proteins (VP1 and VP2). It is designed to induce immunity against Parvovirus B19, thereby preventing infection and its associated complications such as erythema infectiosum. The vaccine has been evaluated in clinical trials for safety and immunogenicity, including studies with and without the MF59 adjuvant. Developed by the National Institute of Allergy and Infectious Diseases (NIAID), it reached Phase 2 clinical development but was not approved for any indication[1][2][3][9].

Other names: parvovirus B-19 vaccinerecombinant human parvovirus B-19 vaccine

Beyond the preview

Go deeper on VAI-VP705.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VAI-VP705.

Explore the full profile